CD8A and neoplasm: Notably, based on the increase in tumor volume over four weeks, depletion of CD8+ T cells significantly abrogated the therapeutic effect of A2-APM (P = 0.042), whereas depletion of CD4+ T cells did not (P = 0.140) (Fig. 5d, Supplementary Fig. 35).